Celltrion Branchburg Biopharmaceutical Facility Expansion
Sector: Manufacturing (Industrial) • Location: Branchburg, New Jersey, United States
Source: The Korea Herald
Celltrion is expanding the manufacturing capacity of its biopharmaceutical facility in Branchburg, New Jersey, from the initially planned 66,000 liters to 75,000 liters, bringing the total drug substance production capacity to 141,000 liters. The site was acquired from Eli Lilly for $330 million in the previous year.
Project Information FAQ
Project Information
Want to explore the full details? View the full report
Participants
Sponsoring Agency | Obfuscated Data |
Company | Obfuscated Data |
Status
Original status | planned |
Taiyo status | Obfuscated Data |
Taiyo last update | 00-00-0000 |
Available timestamps | 00-00-0000 |
Available timestamp type | Obfuscated Data |
Contact
Contact name | Obfuscated Data |
Phone | 0000000000 |
ObfuscatedData@email.com | |
Address | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Description
Description | Celltrion is expanding the manufacturing capacity of its biopharmaceutical facility in Branchburg, New Jersey, from the initially planned 66,000 liters to 75,000 liters, bringing the total drug substance production capacity to 141,000 liters. The site was acquired from Eli Lilly for $330 million in the previous year. |
Original sub-sector | Obfuscated |
Original Currency | USD |
Original budget | 000000000000000 |
Procurement method | Obfuscated Data |
Budget | 000000000000000 |
Location
Region | Obfuscated |
Country | Obfuscated |
State | Obfuscated Data |
County | Obfuscated |
Location | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Source
Source reliability | High |
Data quality score | 100% |
Source | Obfuscated Data |
URL | obfuscated_data,obfuscateddata.com |
More Details
Project Type | Obfuscated Data |
Article Published Date | Obfuscated Data |